User blogs
Novo Nordisk has secured approval for Liraglutide powder (liraglutide) from the US Food and Drug Administration (FDA) to treat paediatric patients aged ten years or older with type 2 diabetes.
Victoza is claimed to be the first non-insulin drug approved to treat the condition in paediatric patients. It has been used for adult patients since 2010.
Acting director at the FDA Center for Drug Evaluation and Research’s Division of Metabolism and Endocrinology Products (DMEP) Lisa Yanoff said: “Victoza has now been shown to improve blood sugar control in paediatric patients with type 2 diabetes.
“The expanded indication provides an additional treatment option at a time when an increasing number of children are being diagnosed with this disease.”When administered, Victoza works by creating the same effects in the body as the glucagon-like peptide (GLP-1) receptor protein in the pancreas and improves blood sugar levels.
Victoza slows digestion, prevents the liver from making too much glucose, and helps the pancreas produce more insulin when needed.
It can also be used to reduce the risk of major adverse cardiovascular (CV) events in adults with type 2 diabetes and established CV disease.
Novo Nordisk carried out several placebo-controlled trials in adults and one placebo-controlled trial with 134 pediatric patients to evaluate the efficacy and safety of Victoza for reducing blood sugar in patients with type 2 diabetes.
The drug is not a substitute for insulin and is not indicated for patients with type 1 diabetes or those with diabetic ketoacidosis. No clinical trials were conducted to study the effect of the drug on major adverse CV events in paediatrics.
LISBON – The investigational glucagon-like peptide (GLP)-1 receptor agonist semaglutide added to standard care for type 2 diabetes mellitus (T2DM) resulted in clinically significant weight loss over 2 years in the SUSTAIN-6 phase 3 trial.
Participants treated with semaglutide in the study lost an average of
3.6 to 4.9 kg, depending on the dose they were given (0.5 mg or 1.0
mg), which was significantly (P less than .0001) more than those who
were randomized to matching placebos (-0.7 mg and -0.5 mg).“A
dose-response effect was observed on weight loss with semaglutide
treatment,” study investigator Agostino Consoli, MD, reported at the
annual meeting of the European Association for the Study of Diabetes.
Semaglutide is under development by Novo Nordisk and is currently under
review by regulatory agencies in the United States, Europe, and Japan.
It has 94% homology to human GLP-1 and modifications have been made to
help it avoid degradation and which give it a half-life that allows it
to be given once a week.
SUSTAIN 6 is part of an ongoing phase 3
program and is a long-term outcome study with the primary objective of
evaluating the cardiovascular safety of semaglutide. Effects on macro-
and microvascular complications, glycemic control, body weight, body
mass index and weight circumference are key secondary endpoints,
together with assessment of its overall safety and tolerability.GHRP-2 powder,GHRP 2 powder
Other trials in the program, have evaluated treatment with semaglutide
as monotherapy (SUSTAIN 1; Lancet Diabetes Endocrinol. 2017;5:251-60) or
versus other treatments including sitagliptin (Januvia, Merck; SUSTAIN
2; Lancet Diabetes Endocrinol. 2017;5:341-54), exenatide extended
release (Bydureon, AstraZeneca; SUSTAIN 3), or insulin glargine (SUSTAIN
4), as add-on to basal insulin with or without metformin (SUSTAIN 5),
and most recently, versus dulaglutide (Trulicity, Eli Lilly; SUSTAIN 7).
SUSTAIN 6 involved 3,297 people with T2DM with established cardiovascular disease or chronic kidney disease or otherwise identified as being at increased cardiovascular risk, according to Dr. Consoli, who is an endocrinologist and professor at the University of Chieti-Pescara, Italy. The results of the primary endpoint have been reported (N Engl J Med. 2016; 375:1834-44) and showed that the composite rate of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke was significantly lower among patients receiving semaglutide than among those receiving placebo. The hazard ratio for the reduction in the composite endpoint was 0.74 (95% CI, 0.58-.95; P less than .001 for noninferiority).
Results of the secondary analyses reported by Dr. Consoli at EASD 2017 showed that semaglutide could help more patients than placebo achieve significant weight loss, which could help further reduce their cardiovascular risk. He reported that a 5% or greater weight loss at 2 years was achieved by 36% and 47% of patients treated with semaglutide 0.5 mg and 1 mg groups, respectively, and by 18% and 19% of patients in the matching placebo groups (P less than .0001 for both comparisons). A 10% or greater weight loss was achieved by 13% and 21% of the semaglutide-treated patients and by 6% and 7% of those given placebo.
“The effect of weight was not dependent on BMI [body mass index] at baseline,” Dr. Consoli said, emphasizing that there was a consistent reduction in the weight in all BMI categories. Importantly, Dr. Consoli observed, the effects of semaglutide on weight seen were not driven by just a few patients losing weight, and around 80% of patients in the study experienced some degree of weight loss.
“As expected, the subjects treated with the GLP-1a had more GI [gastrointestinal] effects,” Dr. Consoli reported. Nausea or vomiting were reported in twice as many patients treated with semaglutide 0.5 mg (21.9%) and 1 mg (27.3%) as their placebo-matched counterparts (10.8% and 10.6%).
A post-hoc analysis found that the effect of semaglutide on weight loss was not likely to be down to these side effects, however, with a similar weight reductions seen in those who did and did not experience nausea or vomiting. The “estimated natural direct effect of treatment” was -2.75 kg for the 0.5 mg dose and -4.32 for the 1 mg dose of semaglutide versus their placebos Dr. Consoli said. GI drove the weigjht loss to a small degree; -0.12 kg and -0.04 kg of weight loss seen in the 0.5 mg and 1 mg semaglutide groups versus their placebos could be ascribed to nausea or vomiting.
In a poster presentation at the meeting, data on another post-hoc analysis from the SUSTAIN phase 3 program were reported. In a responder analysis of T2DM patients achieving glycemic and weight loss thresholds, a greater proportion of those treated with semaglutide achieved clinically meaningful reductions in both glycated hemoglobin (HbA1c) and body weight than those given comparator treatments.
The composite endpoint of at least a 1% reduction in HbA1c and a 5% or greater decrease in body weight was achieved by 25%–35% of patients treated with the 0.5 mg dose of semaglutide, by 38%–56% of those given the higher dose, and by 2%–13% or all comparators (P less than .0001). The higher dose of semaglutide also allowed more people to achieve this endpoint than the lower dose.
Novo Nordisk supported the study. Dr. Consoli disclosed receiving research funding from AstraZeneca and Novo Nordisk and speaker’s bureau or consultation fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co., Merck, Sharp & Dohme, Novartis, Sanofi-Aventis, and Takeda.
Last week, Theratechnologies Inc. began marketing a new medicine called tesamorelin (Egrifta)—licensed for the treatment of excess belly fat in some HIV-positive people. Tesamorelin powder causes the body to produce growth hormone and, as a result, most tesamorelin users can lose some degree of belly fat.
Summary
Tesamorelin is a small molecule that stimulates the brain to produce growth hormone. This hormone helps to reduce the amount of fat in the belly of some HIV-positive people. Tesamorelin does not affect the fatty layer just under the skin (subcutaneous fat) in the face or other parts of the body. Prior to prescribing tesamorelin, Health Canada requires physicians to request a CT scan of a patient’s abdomen to confirm the presence of excess belly fat. Tesamorelin is injected under the skin once daily. In clinical trials, participants who had previously lost belly fat while taking tesamorelin had belly fat return when they stopped taking the drug. In Canada, tesamorelin is expected to cost about $3,000 per patient per month.
Some notes on belly fat, growth hormone and HIV
The fat that accumulates within the belly is called visceral fat. In general, among adults, as the amount of belly fat increases, production of growth hormone decreases. Studies from the 1980s and early-to-mid-1990s suggested that some HIV-positive adults produced lower-than-ideal levels of growth hormone. This reduced production of growth hormone led to changes in the composition of the body—an accumulation of belly fat and a loss of some lean tissue (muscle).
About tesamorelin
Tesamorelin is a small molecule (called a peptide). This drug stimulates a gland in the brain, called the pituitary gland, to release growth hormone. Increased production of growth hormone can cause excess belly fat to diminish.
Clinical trials with HIV-positive people
Tesamorelin has been tested in more than 800 HIV-positive people in well-designed clinical trials. Many participants used tesamorelin for between six and 12 months. This usually resulted in a significant decrease in belly fat compared to placebo (fake tesamorelin). There was a small increase in muscle mass among tesamorelin users and no loss of subcutaneous fat. Levels of triglycerides, a fatty substance in the blood, decreased modestly among tesamorelin users.
When participants who had previously received tesamorelin were instead given placebo, all of the beneficial effects of tesamorelin disappeared.
The hormone insulin is used to help regulate blood sugar levels. After initiating therapy with tesamorelin, the body’s ability to respond to insulin may change. During clinical trials, participants who received tesamorelin were more likely to develop elevated levels of blood sugar because their bodies became less sensitive to the effects of insulin. However, among participants who took tesamorelin for up to one year, problems with blood sugar levels generally resolved.
Verified Market Research represents the Gonadorelin Market 2026. Detail analysis of the parent market based on Key players, present, past and artistic movement information which is able to offer as a profitable guide for all Gonadorelin Market competitors. The analysis Advanced Gonadorelin Market covers an overview of the industry policies that Gonadorelin Market considerably, the price structure of the product obtainable in the market, and their producing chain. Gonadorelin business report is helpful for future strategy development, and to know about Market Drivers, Restraints, Opportunities, and Global Market Size, Share, Growth, Trends, Key players forecast to 2026.Gonadorelin Acetate powder,Gonadorelin powder
The study provides detailed information on the established
Gonadorelin Market with a strong perceptive of world market players and
emerging market associations through market research reports. This also
includes producing Analysis, Size, Share, Supply, Demand, CAGR, Forecast
Trends, Sales, Production, and Business Trends.
The report covers a
detailed analysis of growth factors, constraints, opportunities, and
challenges Gonadorelin Market. It additionally includes extensive
analysis on the latest trends in the market to determine Gonadorelin
Market growth. The report aims to produce an overview of world
Gonadorelin market with careful market segmentation. Also, it analyses
this Gonadorelin market situation and forecasts the market until 2026.
The report covers market dynamics affecting the market throughout the
forecast period. What is more, the report analyses the competitive
scenario, geographic trends, and opportunities within the markets with
regard to all geographic regions. The report conjointly includes the
elaborated company profiles of the key players within the market beside
their market methods.
Delays in rebreeding can be costly. Synchronization programs with producer- and veterinarian-trusted products from Zoetis result in more efficient breeding, saving time and protecting your bottom line. FACTREL® Injection (gonadorelin injection) has an FDA-approved label to be used in conjunction with LUTALYSE® Injection (dinoprost injection) to synchronize estrous cycles to allow for fixed-time artificial insemination (FTAI) in lactating dairy cattle.Gonadorelin Acetate powder,Gonadorelin powder
FACTREL is now available in a larger, more convenient 50-mL bottle. Now you can treat up to 25 cows per bottle of FACTREL compared with just 10 doses in the 20-mL bottle. With more than 12,000 total cows studied, you can have confidence that FACTREL is effective. Now you can adapt a reproduction program that fits your management needs, with flexible schedule and dosing with FACTREL and LUTALYSE.
FACTREL is also indicated for the treatment of ovarian follicular cysts in cattle. When used in cattle with ovarian follicular cysts, treatment effect is to reduce the number of days to next estrus.
It’s more than just the bottle. Zoetis works with you to make appropriate decisions about the use of LUTALYSE and FACTREL in your herds and to create a comprehensive approach for your reproduction program, so you can set and achieve higher pregnancy rate goals, improving your milk production and increasing the opportunities you have for herd improvement through genetic selection.
It seems contrary to what I've heard before about CJC only being injected once a **TL;DR: Dosage schedule for GHRP6 + CJC?. Say they has 2mg of cjc and 5mg of ghrp in vials; any thing special that 5mgs of ghrp-6) and what will the resulting dosage/concentration be. Will Mod CJC and GHRP6 last longer in NaCL or BW? I know it can be recon in BW for approximately 2 weeks, but what if you want it to.
This seems to be the most effective dosing schedule. This cycle has done the best for most people running CJC + GHRP-6 You can substitute GHRP-2 for. GHRP-6 doses can vary depending on goals and past experience. with doses of a GHRH analogue, such as Mod GRF (CJC without . For reconstitution, users will typically mix 3ml of bacteriostatic water with the powder gently. How to Mix and Store Peptides for its types GHRP Peptides, CJC Peptides, HGH Frag and IGF-1 Peptides. a. to aim at the wall instead of directly at the powder for better dilution and mixing of substances. e. Cjc ghrp 2 dosage instructions >> [ Read Online ] wise to use GHRP along with CJC if you want toThe GHRP 6 can also be used. The only GHRH to consider is tetra-substituted CJC / CJC(without DAC) / modGRF(). They are all GHRP-6 is very potent and makes you quite hungry. GHRP-2 GH pulses should peak within about 10 minutes after dosage. Nice post, the CJC GHRH analog is a very quality substance.
CJC or GRF () – the best choice for the combination. Enhance the effect of GHRP-6 in several times. This combination is currently. Blend CJC NO DAC with GHRP-6 is Stable at room Temperature. Blend CJC NO DAC with GHRP-6 should be refrigerated at temperatures not to. The principal use of CJC is to provide CJC is typically provided in vials . GHRP-6 – 5mg Other Peptides; Peptides; Reconstituting Agents; Research. For short term (per vial use)it's refrigerate I know but long term? The reconstitution agent for both CJC & GHRP-6 is Bacteriostatic Water.
After reconstituting CJC W/O DAC should be refrigerated at temperatures Generally, a product in the GHRH category, including CJC, is chosen as an alternate to using GH, and only rarely GHRP-6 10mg/vial 10vials/kit 1g/bag. Research Calculator to Reconstitute Proteins & Peptides. This tool determines peptide weight in micrograms (mcg) in each graduated unit of a container or. Muscle Building Growth Hormone Releasing Peptide 5mg/vial GHRP-6 guidelines for reconstituting GHRP-6, reconstitute in sterile, bacteriostatic, distilled water, Synonyms: CJC without DAC, CJC w/o DAC, MOD GRF , Neorelin, The most common use of these peptides is to increase GH production.
For the past four weeks, I’ve woken up, stumbled out of bed into the
kitchen, opened the refrigerator, fetched a tiny bottle of something
called “BPC-157” and proceeded to stab myself with an insulin syringe to
inject it into various parts of my body.
OK, OK, lest you be
donning a white lab coat and cringing from that simple description, then
I’ll be more specific: a peptide is a compound consisting of two or
more amino acids linked in a chain, the carboxyl group of each acid
being joined to the amino group of the next by a bond like this: OC-NH.
In the case of BPC 157 powder, the peptide is a sequence of amino acids with a molecular formula of 62 carbons, 98 hydrogens, 16 nitrogens, and 22 oxygen atoms (C62-H98-N16-O22).
Should you care to know the nitty-gritty specifics, that comes out to a fifteen amino acid sequence of the following:
L-Valine, glycyl-L-alpha-glutamyl-L-prolyl-L-prolyl-L-prolylglycyl-L-lysyl-L-prolyl-L-alanyl-L-alpha-aspartyl-L-alpha-aspartyl-L-alanylglycyl-L-leucyl-; glycyl-L-alpha-glutamyl-L-prolyl-L-prolyl-L-prolylglycyllysyl-L-prolyl-L-alanyl-L-alpha-aspartyl-L-alpha-aspartyl-L-alanylglycyl-L-leucyl-L-valine.
Yep, that’s the long, fancy name for BPC-157.
BPC, for reasons you’re about to discover, stands for “Body Protecting Compound”. Your body already makes it in your own gastric juices in very small amounts, where it serves to protect and heal your gut. But if you can get the super concentrated version and get it into your system, it has an extremely high level of biological healing activity just about anywhere you put it
And if many of the amino acids above look familiar to you, there’s
good reason. I’ve talked about them before. I’ve used them orally for
quite some time to heal injuries more quickly, to keep the body in
anabolic state during or post-exercise, and to stave off central nervous
system fatigue during long bouts of exercise. I have a quite
comprehensive article about the oral use of amino acid tablets here.
BPC-157 is surprisingly free of side effects, and has been shown in
research that’s been happening since 1991 to repair tendon, muscle,
intestines, teeth, bone and more, both in in-vitro laboratory
“test-tube” studies, in in-vivo human and rodent studies, and when used
orally or inject subcutaneously (under your skin) or intramuscularly
(into your muscle).
BPC-157 is also known as a “stable gastric
pentadecapeptide”, primarily because it is stable in human gastric
juice, can cause an anabolic healing effect in both the upper and lower
GI tract, has an antiulcer effect, and produces a therapeutic effect on
inflammatory bowel disease (IBD) – all again surprisingly free of side
effects.
As demonstrated in the research studies cited above, BPC-157 also accelerates wound healing, and, via interaction with the Nitric Oxide (NO) system, causes protection of endothelial tissue and an “angiogenic” (blood vessel building) wound healing effect. This occurs even in severely impaired conditions, such as in advanced and poorly controlled irritable bowel disease, in which it stimulates expression of genes responsible for cytokine and growth factor generation and also extracellular matrix (collagen) formation, along with intestinal anastomosis healing, reversal of short bowel syndrome and fistula healing – all of which can extremely frustrating issues in people who have gut pain, constipation, diarrhea and bowel inflammation.
Function
BPC 157 has a strong anti-inflammatory activity in both acute and chronic inflammation models. In fact, preliminary results in clinical trials suggest that BPC 157 may become an important therapeutic tool for the treatment of inflammatory bowel disease. BPC 157 was shown to accelerate wound healing and to have a marked angiogenic effect. In addition, it significantly facilitates the healing of bone fracture in rats. This peptide also exhibits an osteogenic effect significantly improving the healing of segmental bone defect. BPC 157 accelerates the healing of transected rat Achilles tendon and transected rat quadriceps muscle.
Application
1.BPC-157 acts in a glucose-dependent manner, meaning it will stimulate insulin secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia.
2.BPC-157 It has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies).
3.BPC-157 It decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride.
4.BPC-157 It lowers blood triglyceride levels.
"Innovation, quality and reliability are the core values of our company. These principles today more than ever form the basis of our success as an internationally active mid-size company for Teriparatide Acetate , Teriparatide acetate , Exenatide acetate , Our products and solutions are sold to the Middle East, Southeast Asia, Africa, Europe, America and other regions and are favorably appraised by clients. To benefit from our strong OEM/ODM capabilities and considerate services please contact us today. We will sincerely create and share success with all clients.Teriparatide Acetate powder
1 .Appearance White powder
2 .Water Content(Karl Fischer) <10.0% 3 .Acetate Content(by HPLC) ≤15.0% 4 .Amino Acid Composition ±10% of theoretical 5 .Purity(by HPLC) ≥98.0% 6 .Single Impurity(by HPLC) ≤1.0% 7 .Peptide Content(by %N) ≥80% 8 .Assay(By Anhydrous, Acetic Acid-free ) 95.0~105.0% 9 .Bacterial Endotoxins ≤5EU/mg 6.Packing: plastic vial(dedicated for peptide packing) or glass vial, quantity according to your detail requirement. 7.Storage: a cool(2~8 °C) & dry place protected from light, keep package close when not in use.
There are a number of symptoms of the error code 412 Cisco VPN client and these are obvious when it crashes an active programme. It can also crash the PC in its entirety if the error occurs in a similar programme. Often the message will pop up saying “Cisco VPN Client connection error reason 412” and you’ll notice that the computer starts to run much slower, even not reacting to the mouse or keyboard. The final symptom of this is when the computer actually freezes for short bursts at a time. @$#f$234
There are a number of causes that trigger Cisco VPN client connection error reason 412. These include corrupt downloads of the Cisco VPN software, corruption within the Windows registry and also from malware that has made its way onto the computer. In some cases the error can be from another programme where there has been a mistake in deleting Cisco files.
How to fix Cisco VPN error 412
Fixing the error can be time consuming with some solutions being easier than others. With that in mind we will put the easiest ones first. First you should repair any registry entries that could be associated with the error 412 VPN connection. You will also need to do a full scan of any malware on your computer, deleting any issues that you find. If these two steps have not yet yielded any successful results, you’ll need to move on to cleaning out the system junk. This is a collection of temporary files that your computer collects over time. This can take up space, causing this error to occur. Updating your device drivers can also help minimise the chances of the error 412 VPN Cisco client occurring. Doing a restore of the entire Windows system can also be beneficial, though we don’t recommend doing that unless you really need to.
If the message says Cisco VPN error 412 remote peer no longer responding, you may need to go a step further and actually remove the Cisco client programme from your computer entirely. Then you’ll need to reinstall it, hopefully in the correct fashion, erasing any issues. The absolute final thing for your Cisco VPN 412 error fix is to run a Windows system file check or even to update and reinstall the entire Windows software. However, for the error 412 Cisco VPN Windows 8 and Windows 7 are the only operating systems that seem to be mainly affected. VPN download
https://www.ritavpn.com/blog/
https://www.ritavpn.com/blog/i-am-ritavpn/
https://www.ritavpn.com/blog/internet-security-and-privacy/